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Siglec-10 is an inhibitory I-type lectin selectively recognizing sialoglycans
exposed on cell surfaces, involved in several patho-physiological processes. The
key role Siglec-10 plays in the regulation of immune cell functions has made it a
potential target for the development of immunotherapeutics against a broad
range of diseases. However, the crystal structure of the protein has not been
resolved for the time being and the atomic description of Siglec-10 interactions
with complex glycans has not been previously unraveled. We present here the
first insights of the molecular mechanisms regulating the interaction between Si-
glec-10 and naturally occurring sialoglycans. We used combined spectroscopic,
computational and biophysical approaches to dissect glycans’ epitope mapping
and conformation upon binding in order to afford a description of the 3D com-
plexes. Our outcomes provide a structural perspective for the rational design
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Siglecs (sialic acid-binding immunoglobulin-like lectins) constitute a family of cell surface immunomodula-
tory receptors belonging to the immunoglobulin (Ig) superfamily that act as critical regulators of immune
system (Crocker et al., 2007; Duan and Paulson, 2020; Macauley et al., 2014; Läubli and Varki, 2019) through
the specific recognition of sialic acids, hallmarks of vertebrate self-glycans. Their ability to control the im-
mune balance, triggering tolerogenic or immunogenic responses, explains why aberrant sialic acid-Siglec
interactions are linked to a broad spectrum of pathologies including infection, autoimmunity, and cancer
(Bochner and Zimmermann, 2015; Lübbers et al., 2018; Adams et al., 2018). Furthermore, feared human
pathogens evolved the ability to shield their envelope glycans with sialic acid, mimicking Self Associated
Molecular Patterns (Liu et al., 2017; Chang and Nizet, 2014) and exploiting the interaction with inhibitory
Siglecs to escape host immune surveillance. In this context, the Siglec-sialoglycan axis is, therefore, an
emerging attractive therapeutic target to prevent or affect the course of several immune (cancer, autoim-
mune, and infectious) diseases.
Siglecs are mainly expressed on innate and adaptive immune cells and display a broadly similar domain
organization. These single-pass transmembrane proteins possess an extracellular N-terminal V-set
domain, involved in the recognition of specific sialoglycans, and most of them encompass, in their cyto-
plasmic tails, one or more immunoreceptor tyrosine-based inhibitory motifs (ITIMs), involved in negative
intracellular signaling pathways (Crocker et al., 2007; Duan and Paulson, 2020; Macauley et al., 2014).
Siglec-10 is an inhibitory receptor belonging to the CD33-related Siglecs family (Whitney et al., 2001) ex-
pressed on dendritic cells, human leukocytes, and B cells (Chen et al., 2009; Bandala-Sanchez et al.
2018, 2020). It is characterized by five extracellular domains and three tyrosine-based motifs in its cyto-
plasmic tail, exhibits only 40%–48% homology to other members of CD33-related Siglecs group, and
furthermore can bind with high affinity to a-2,6- or a-2,3-sialoglycans as well as to GT1b ganglioside (Rapo-
port et al., 2003). Siglec-10 is the human homolog of murine Siglec-G, which is known to regulate the toler-
ance of the B1 sub-class of B cells, dampening autoimmune responses upon sialoglycans recognition,
although with yet unknown molecular mechanisms (Chen et al., 2014). Moreover, the leading cause of
bacterial gastroenteritis worldwide and a major causative trigger of the Guillain-Barré syndrome,iScience 23, 101231, June 26, 2020 ª 2020 The Author(s).





ArticleCampylobacter jejuni (Phongsisay, 2016), promotes an anti-inflammatory response mediated by its recog-
nition by Siglec10 through the pseudaminic acid (sugar chemically related to sialic acid) decorating the
bacterial flagellum (Stephenson et al., 2014). On the other hand, the interaction of Siglec-10 with the heavily
glycosylated, mucin-like cell surface protein CD24, exposed on a variety of tumor cells, is an innate immune
checkpoint essential for mediating anti-tumor immunity (Barkal et al., 2019; Zhang et al., 2015). Interest-
ingly, expression of CD24 and Siglec-10 has also been observed at the fetal-maternal interface during
the first 3 months of pregnancy, suggesting a possible role of Siglec-10 in establishing the immune toler-
ance in the placenta between the fetus and the mother (Sammar et al., 2017).
To decipher the complex mechanisms regulating host immune suppression following sialoglycan recogni-
tion by Siglec-10, the detailed knowledge of the molecular recognition and binding events represents a
mandatory step. In turn, these may be translated into highly specific novel diagnostics and therapeutics,
able to exploit Siglec-10 anti-inflammatory pathways for the modulation of immune cellular responses.
In this context, and given the lack of any structural knowledge on Siglec-10, we used here amultidisciplinary
strategy, combining spectroscopic, computational, and biophysical approaches, providing the first in-
sights into the molecular mechanisms regulating Siglec-10 recognition of cognate (naturally occurring)
sialyloglycans, demonstrating the critical role played by the glycans’ conformation.RESULTS
Here, we tackled the important question of how Siglec-10 recognizes and binds, at a molecular level,
different sialylated glycans, including 30SLN and 60SLN, 1 and 2 respectively, as well as naturally occurring
complex-type N-glycans (Figure S1). By coupling spectroscopic approaches (such as NMR, fluorescence
spectroscopy) to biochemical and computational methodologies (such as homology modeling, docking,
molecular dynamics, and CORCEMA-ST calculations) we have obtained and validated 3D models of
ligand-protein complexes. We therefore provide the dynamic characterization of the molecular interac-
tions occurring in solution between Siglec-10 and cognate sialoglycans, mapping their binding epitopes
and defining their bioactive conformation.Siglec-10 Binding Specificities
The binding specificities of Siglec-10 were primarily evaluated by a solid-phase enzyme immunoassay,
ELISA, and fluorescence analysis, using a recombinant soluble form of the protein in which the full extra-
cellular region was fused to the Fc region of human IgG1. As depicted in Figure 1A, the ability of Siglec-
10 to recognize terminal a2,6- and a2,3-linked sialic acid on various sialoglycans was demonstrated in
ELISA experiments, indicating that Siglec-10 similarly recognized all the sialylated conjugates tested
with a significant optical density (OD) compared with the negative control (PBS). Analogously, the fluores-
cence titration of increasing amounts of sialoglycans into a fixed concentration of Siglec-10 indicated that,
regardless of the nature of the Neu5Ac-Gal linkage, both a2,3- or a2,6-linked sialoglycans could interact
with the protein with binding constants in the micromolar range (Figure 1B).Molecular Basis of Sialoglycans Recognition by Siglec-10
A combination of ligand-based NMR techniques and computational studies was employed to evaluate the
epitope mapping (group epitope mapping) and the bioactive conformation of different sialoglycans (Fig-
ure S1) upon binding to Siglec-10.
Group Epitope Mapping and Bioactive Conformation of 1
The saturation transfer difference (STD) NMR analysis (Marchetti et al., 2016; Meyer and Peters, 2003; Mayer
and Meyer, 1999) (Figure 2) conducted on 30-Sialyl-N-acetyllactosamine 1 in the presence of Siglec-10
confirmed the binding and allowed a detailed description of the structural elements of 1 when accommo-
dated into the protein binding pocket (Figure 2A). The comparison of the STD NMR spectrum with the cor-
responding reference (off-resonance) showed that only some protons of ligand 1 exhibited STD enhance-
ments. STD effects were calculated by use of (I0 – Isat)/I0, where (I0 – Isat) is the intensity of the relative
signal in the STDNMR spectrum and I0 is the peak intensity of an unsaturated reference spectrum (off-reso-
nance). Siglec-10 gives themaximum saturation transfer to the acetyl group protons belonging toK residue
of trisaccharide 1, so this STD signal was set at 100% and the other ligand 1 protons percentages were
derived accordingly. The sialic acid residue (K) resulted essential for the interaction with Siglec-10, giving
the most significant contribution to the molecular recognition process. Indeed, the N-acetyl group of K2 iScience 23, 101231, June 26, 2020
Figure 1. Siglec-10 Binding to Sialoglycans
(A) Siglec-10 binding to sialylated conjugates detected by ELISA. ELISA plates were coated with synthetic conjugates
carrying terminal sialic acids with a2,3 or a2,6 linkages, followed by the addition of a human Fc chimera of Siglec-10. The
detection of the interaction was evaluated with an anti-Human IgG-HRP (horseradish peroxidase) conjugate followed by
substrate addition. The experiment has been performed three times in duplicate, showing similar results. Error bars
indicate standard deviations of a representative experiment performed in duplicate. Data are normalized on BSA-treated
wells used as blocking agent.
(B) Fluorescence titration. Fluorescence spectra of Siglec-10 (black lines) and in the presence (colored lines) of increasing
amounts of the ligand sialoglycan 1 (upper panel) and 2 (lower panel), respectively. The insets report the binding isotherm




Articleshowed the highest STD signal, followed by the protons signals H-6 and H-7 affected by a rather high satu-
ration transfer, close to 80%. Significant STD enhancements, around 60%, were also observed for protons
H-5, H-8 and H-9, indicating their strong involvement in the interaction, whereas weaker STD signals were
observed for the diastereotopic H-3 protons of K and for some protons of the galactose unit B. Conversely,
theN-acetylglucosamine residue (A) almost did not contribute to the binding process, as confirmed by the
absence of any corresponding STD signal. We have also constructed the STD build-up curves (Angulo and
Nieto, 2011; Yan et al., 2003) (Figure 2C, Table S1) to overcome possible artifacts due to different protons
T1 relaxation times and thus to precisely map the interacting epitope of ligand 1. The strong involvement of
K in the binding was confirmed, as well as the orientation of B pointing toward the protein binding site.
The determination of the epitope map of trisaccharide 1 (group epitopemapping) was complemented with the
analysis of the conformational behavior of 1 in its free state and upon binding with Siglec-10. The accessible
conformational space of 1 was accomplished by molecular mechanics (MM) and molecular dynamics (MD) sim-
ulations, together with nuclear overhauser effect (NOE)-derived experimental data, to define the preferred
torsional angles ligand 1 adopted in the free and bound states. In the free state, a conformational equilibrium
was observed between three main conformers, namely, g–/g+/t, differing by the value of the F (C1-C2-O-C3’)
torsion angle between Sia and Gal residues (60/60/180 data not shown) (Poppe et al., 1997; Forgione
et al., 2020). It is worth noting that, in terms of topology, all these conformers adopt a rather extended confor-
mation in which the sugar units fill a cone-like region of space (Xu et al., 2009) governed by a value of q higher
than 110, where q represents the angle between the carbon C-2 of Neu5Ac residue and C-1 atoms of the sub-
sequentGal andGlcNAcunits (Chandrasekaran et al., 2008). During theMDsimulation, ligand 1mainly explored
the g– (F=60) and t (F= 180) conformations; conversely, theJ torsion angle (C2-O-C3’-H3’) remained stable
along the dynamics around an average value of 11. MD simulation results were supported by nucleariScience 23, 101231, June 26, 2020 3
Figure 2. Analysis of the Group Epitope Mapping and Bioactive Conformation of Trisaccharide 1 upon Binding with Siglec-10
(A) STD-derived epitope mapping on the molecular envelope of ligand 1 in its bioactive minus gauche conformation.
(B) Reference 1H NMR spectrum (black) and 1D STD NMR spectrum (red) of the Siglec-10/ligand 1 mixture (molecular ratio 1:100, T = 298 K).
(C) STD build-up curves were derived by the monoexponential equation STD = STDmax[1 – exp(–ksatt)], constructed by fitting the STD factors at different
saturation times, from 1 to 5 s. In the exponential curve, STD represents the observed signal intensity, STDmax is the asymptotic maximum of the curve, ksat is
the observed saturation rate constant, and t is the saturation time.




Articleoverhauser effect spectroscopy (NOESY) NMR analysis (Marchetti et al., 2016; Poveda and Jiménez-Barbero,
1998), confirming the existence of an equilibrium between different conformations of 1 in its free state (Table 1).
As for the bound state, transferred-NOESY (tr-NOESY) NMR experiments were acquired to highlight
changes in the conformation of 1 when interacting with Siglec-10. The analysis of tr-NOESY demonstrated
a selection of the g– conformer (F/J torsion angles of60/11) of 1 upon binding. In particular, in the tr-
NOESY spectrum we observed a decrease of the cross-peak intensity of B3-K3ax, an increase of B3-K8, and
the absence of B3-K3eq cross peak (Figure S2, left panel). The crucial inter-residual
1H–1H distances (Table
1) were extracted by construction of NOE build-up curves, clearly revealing a preference for the g– confor-
















H3ax Neu5Ac -H3 Gal 2.86 3.90 4.10 3.11 2.18
H3eq Neu5Ac -H3 Gal 3.65 – 4.40 2.03 3.40
H8 Neu5Ac -H3 Gal 3.41 3.19 3.36 6.17 4.31
Table 1. Conformational Behavior of 1—Key Intra-Molecular Neu5Ac-Gal Distances
The proton-proton distances were obtained by the sel-NOE experiments, acquired at different mixing times irradiating the




ArticleGroup Epitope Mapping and Bioactive Conformation of 2
The binding profile of 60-sialyl-N-acetyllactosamine 2 (Figure S1) by Siglec-10 was investigated by means of
STDNMR (Figure 3); changes in the relative enhancements and differences in themultiplicity of STD signals
were detected. The epitope mapping of ligand 2 highlighted the protons specifically involved in the inter-
action with Siglec-10. The strongest STD signal belonged to theN-acetyl group of non-reducingNeu5Ac, K
residue, providing an STDepitope fit value of 100% (Table S2). As for the other proton signals belonging to
sialic acid, only H-6 and H-7 showed high STD effects, thus pointing significantly close to the receptor-bind-
ing pocket, whereas the other protons exhibited STD values around or below 30%. Furthermore, the galac-
tose moiety (B) of 2 received a significantly weaker magnetization transfer from the protein, corresponding
to low STD values, and thus seemed less involved in the interaction with Siglec-10 if compared with 1. The
N-acetylglucosamine (A) of 2 revealed no STD enhancements, suggesting that it was likely solvent
exposed.
The conformational behavior of 2 in its free and bound states was determined by combining NMR and
computational techniques. Here, the Neu5Ac-a-(2-6)-Gal glycosidic linkage was defined by an extra torsion
angle (Poppe et al., 1992), namely, u (O06C06C5’O05), that influences the entire three-dimensional
structure of 2. In detail, three different rotamers differing in the u value can coexist in solution, namely,
gg/tg/gt (Patel et al., 2014) (u 60/180/60, respectively), the gt conformer being the most populated
in the free state (Di Carluccio et al., 2019). Comparing the experimental NOE-derived and theoretical dis-
tances (Table 2, Figure S2 right panel), a preference was evident for the geometry with4/c/u torsion angles
of 60/180/60 around Sia-Gal linkage (Family I, gt conformer) (Poppe et al., 1992) both in the free and
bound states. The gt preference of 2 corresponded to a bent conformation that implicates the back-folding
of the sialic acid residue and was characterized by an open umbrella-like topology (q angle below 110 [Xu
et al., 2009]) as supported by the small NOE contact between H-5 of sialic acid residue and the methyl
group of N-acetylglucosamine (Figures 3C and S2 right panel).
Homology Modeling of Siglec-10
Since the crystal structure of Siglec-10 has not been solved yet, we opted to predict the protein 3D structure
by means of computational methods, with the aim to describe a 3D model of Siglec-10/sialoglycans com-
plexes. The homology model of the CRD (carbohydrate recognition domain) of Siglec-10 was derived by
using Siglec-8 (PDB–ID: 2N7A), Siglec-7 (PDB-ID: 2HRL), Siglec-5 (PDB-ID: 2ZG2), and Siglec-3 (PDB-ID:
5IHB) as structural templates (see Supplemental Information for further details). The models were
computed with different homology modeling servers and then refined by MD simulations as implemented
within the Amber 14 package (Case et al., 2014) (Figures S3 and S4). The structural models of Siglec-10 dis-
played high similarity along with the corresponding templates. By comparing such models, the character-
istic fold of the V-set domain of Siglecs CRD was observed, even though some differences occurred in the
conformation of the variable region of Siglecs, namely, the inter-strand CC0 loop (Figure S4).
To select the most accurate model, a detailed analysis was performed, focusing the attention on the orien-
tation of the binding-site residues and the flanking loops. Four promising models (Figure S4) were subse-
quently used for docking calculations with sialoglycans by means of Autodock 4.2 (Morris et al., 2009).
Selected ligand-protein complexes were then submitted to MD simulations to monitor the stability in
solution (Figures S4B and S4C). The most consistent protein/ligand complexes obtained from docking
and MD were subjected to CORCEMA-ST (complete relaxation and conformational exchange matrix)iScience 23, 101231, June 26, 2020 5
Figure 3. Analysis of the Group Epitope Mapping and Bioactive Conformation of Trisaccharide 2 upon Binding
with Siglec-10
(A) Reference 1HNMR spectrum (black) and 1D STDNMR spectrum (red) of the Siglec-10/ligand 2mixture (molecular ratio
1:150, T = 298 K).
(B) STD build-up curves derived by fitting the experimental data to the monoexponential equation STD = STDmax[1 –
exp(–ksatt)].




Articlecalculations (Jayalakshmi and Krishna, 2002), a program that evaluates the predicted STD-NMR intensities
for a proposed molecular model of a ligand-receptor complex. In order to validate the given complexes,
the predicted fractional intensity changes for different ligand protons were compared with the experi-
mental STD-NMR data through a normalized root-means square deviation (RMSD) value, also known as
the NOE R factor. Thus, docking, MD simulations, and CORCEMA-ST analysis permitted the selection of
MODEL IV as the optimal Siglec-10 model, predicted by using Siglec-7 structural template (Figure S4). It
is worth to note that the selected sialoglycans/Siglec-10 complexes exhibited not only the best agreement
between theoretical and experimental STD data but also the highest stability along the simulations.
3D-View of Siglec-10 in Interaction with 1
A three-dimensional view of the Siglec-10/trisaccharide 1 complex was achieved by computational studies.
Docking calculations were performed using trisaccharide 1 in each of its three possible conformations (g-,
g+, t). Selected docked poses were then submitted to MD simulations and subjected to CORCEMA-ST cal-
culations. The best fit between predicted and experimental data, corresponding to the lowest NOE R fac-
tor value (0.29), was given by the MODEL IV/1 complex reported in Figure 4 (upper panel), carrying the
trisaccharide 1 in the extended g- conformation, denoting good agreement between experimental and
predicted STD data. Of note, the profiles of the theoretical STD data achieved for the other two models,
bearing the trisaccharide 1 in g and t conformation, respectively, were far from the experimental STD ef-
fects, resulting in higher NOE R factor values and suggesting that these models should be excluded (Fig-
ure S6). The best selected Siglec-10/ligand 1model (Figure 4, upper panel) displayed good stability along
the MD simulations, further validating the preference of the ligand for the g- conformation in the bound
state, as suggested by the stability of the F glycosidic torsion angle between the sialic acid and the galac-






F = 60 J = 180
U = 60
Family II
F = 180 J = 180
U = 60
H1 Gal -H4 GlcNAc 2.52 2.50 2.40 2.40
H3eq Neu5Ac -H3 Gal / / 4.93 3.84
H8 Neu5Ac -H3 Gal / / 4.58 3.37
H3eq Neu5Ac -H3 Gal 4.20 4.30 4.43 2.53
H8 Neu5Ac -H3 Gal 4.10 4.30 4.25 2.35
H5 Neu5Ac -CH3GlcNAc 4.00 4.00 4.30 9.60
Table 2. Conformational Behavior of 2—Key Intra-Molecular Distances
Intra- and inter-residual proton-proton distances extracted from the results of the MD simulations and translated into NOE
contacts according to a full-matrix relaxation approach. The corresponding average distances obtained for the simulation




ArticleExamination of the binding mode of 1 by Siglec-10 (model IV) revealed the typical architecture of Siglecs
binding site, characterized by a solvent-exposed, highly positively charged cavity constituted by the C, F,
and G b strands and surrounded by the CC’ and GG’ loops (Figure 4 upper panel and Figure S4). The
Neu5Ac residue was placed at the top side of the G-strand, making several polar interactions with the
receptor amino acids. Such interactions established by the Neu5Ac moiety were previously reported
to be crucial for recognition of sialylated glycans by other CD33-related Siglecs (Crocker et al., 2007; At-
tril et al., 2006, 2008; Pröpster et al., 2016). During the 100ns MD simulation of the model IV/1 complex, it
was possible to observe high stability of the complex until 50 ns, without applying any restriction (Fig-
ure S5 upper panel). Alongside the simulation, ligand-protein interaction analysis identified relevant po-
lar contacts between the trisaccharide 1 Neu5Ac unit and the residues located into the binding site of
Siglec-10, namely, Arg-119, Arg-127, Asn-129, along with hydrophobic interactions involving Phe-21
and Tyr-128. In detail, the sialic acid carboxylate established a stable ionic interaction with the ammo-
nium group from the highly conserved Arg-119. Furthermore, the hydroxyl groups of the glycerol chain
of Neu5Ac formed hydrogen bonds with Asn-129 and Arg-20 residues of the protein. Also, a polar inter-
action between the acetamide moiety of Sia and Arg-127 residue was found. The H-bonds between the
OH group at C-8 position of 1 and Asn-129 amide, and the OH group at C-9 and Arg-119 CO group were
maintained along most of the simulation. The NH group of Neu5Ac acetamide moiety formed a
hydrogen bond with the Arg-127 backbone, which was steadily held along the simulation. Additionally,
Tyr-128 established key CH-p interactions with the C-7 and C-9 hydrogens of sialyl glycerol moiety. The
only buried portion of 1 was the methyl group of Neu5Ac unit, which laid in a groove formed by Phe-21
and Tyr-128, thereby establishing CH-p interactions. In the complex, the Gal residue formed polar con-
tacts with the binding-site residues of the protein, namely, Asn-129 and Glu-66, whereas the GlcNAc res-
idue pointed far from the receptor surface, as confirmed by STD NMR analysis (Figure 4 upper panel and
Figure S5 upper panel).
According to CORCEMA-ST analysis (Figure 4C upper panel), the protons belonging to the Neu5Ac units
exhibited the highest STD effects, confirming that Neu5Ac was the major determinant of the interaction
with Siglec-10. The strong STD value observed for the methyl group of the acetamide moiety of sialic
acid corresponded to the close contacts between this moiety and Phe-21 and Tyr-128 side chains. Further-
more, the stable hydrogen bond established between acetamidemoiety and Arg-127 backbone reinforced
this interaction. Regarding STD data on the sialic acid glycerol side chain, the higher STD effect observed
for the H-7 in comparison with H-8 and H-9 was ascribable to the CH-p interaction between H-7 and Tyr-
128. Although the hydroxyl groups at positions 8 and 9 made direct hydrogen bonds with the backbone of
Asn-129, the protons H-8 and H-9S pointed away with respect to the Tyr-128 group, consequently leading
to an STD effect lower than the other Neu5Ac protons. Despite the contacts between the CC0 loop of the
protein with the galactose ring in trisaccharide 1 bound conformation, weaker STD effects were predicted
for the Gal protons. In addition, the STD value estimated for the N-acetylglucosamine moiety were negli-
gibly small, thus confirming that the residue was not involved in the interaction with the protein (Figure 4
upper panel).iScience 23, 101231, June 26, 2020 7
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Figure 4. Docking/MD and CORCEMA-ST Analysis of 1 (Upper Panel) and 2 (Lower Panel) in the Interaction with
Siglec-10
(A) Best binding pose (STD, tr-NOESY, and MD based) for the docking of the ligand bound form into binding site of
Siglec-10 model derived by using Siglec-7 as structural template. The carbohydrate and interacting amino acids are
shown as sticks. Dashed black lines represents hydrogen bonds.
(B) Two-dimensional plots representing the interactions between the ligand and the residues of the binding site of Siglec-
10 model. Dotted arrows indicate hydrogen bonds with functional groups from side chains and solid arrows those with
functional groups of the backbone. The residues shown are close to the ligand and participate in hydrophobic and polar
interactions.
(C) Comparison between experimental (dashed line) and theoretical (solid line) STD data for the best model of ligand




Article3D-View of Siglec10 in Interaction with 2
To get a three-dimensional perspective of the interaction of trisaccharide 2 with Siglec-10 CRD, docking
calculations were performed by using the previously selected Siglec-10 structure and following a similar
protocol to that for trisaccharide 1 (see above and Supplemental Information for further details). MD sim-
ulations of the most representative complexes were performed to assess the stability of the binding poses
(Figure S4C); then, with the aim of selecting the best 3D model of interaction in line with STD data, COR-
CEMA-ST calculations were carried out. The lowest NOE R factor, with the value of 0.26, was obtained for
the complex reported in the lower panel of Figure 4 in which the trisaccharide 2 adopted a gt conformation
(see also Figure S6B).
The terminal sialic acid was again the major determinant of ligand binding, establishing several polar in-
teractions with the protein, which were comparable with those observed for the trisaccharide MODEL
IV/1 complex (Figure 4 upper panel). As in trisaccharide 1, the methyl group of Neu5Ac lies in the hydro-
phobic groove defined by Phe-21 and Tyr-128 (Figure 4 lower panel). Furthermore, the Neu5Ac residue of 2
formed the key salt bridge between its carboxylate and the guanidinium group of Arg-119; hydrogen
bonds between the backbone of Asn-129 and the hydroxyl groups of the glycerol chain, namely, OH-8
and OH-9, were also observed. Notably, these interactions remained stable along the MD simulation. As
observed for trisaccharide 1, a direct involvement of the Gal unit of 2 in the binding was evident with the
hydrogen bond occurring between the Gal hydroxyl group in position 3 and the Glu-66 residue. Further-
more, the protein did not engage interactions with the GlcNAc unit of 2.
From the MD simulation performed on the selectedMODEL IV/2 complex, it was possible to observe that,
although 2 remained steadily anchored to the protein via the sialic acid moiety, the bound ligand explored
both gt and tg conformations along the dynamic (Figure S5 lower panel). The u angle, indeed, fluctuated
between u = 60 and u = 180. This suggested that ligand 2 displayed higher conformational flexibility,
even upon binding, with respect to ligand 1. However, from the CORCEMA-ST analysis, the best fit be-
tween experimental and theoretical data was obtained for the gt conformer (Figure 4C lower panel). In
detail, the highest predicted STD value was given by the methyl group of the N-acetamide moiety of
Neu5Ac. This could be ascribable to the vicinity of the acetamide group toward the aromatic residues
Phe-21 and Tyr-129. For the same reasons discussed for 1, the H-7 of the sialic acid glycerol side chain
of trisaccharide 2 displayed higher STD effects with respect to the protons in position 8 and 9. Despite
the proximity of the CC0 loop of the protein to the galactoside ring of the trisaccharide 2, lower STD effects
were observed for the galactose moiety of 2. In complete agreement with the experimental STD data, no
significant STD effects were predicted for the GlcNAc moiety (Figure 4 lower panel).
Molecular Interaction between Siglec-10 and Complex-type N-glycans
The interaction between naturally occurring glycans and Siglec-10 has also been investigated in order to
unveil if and how a different presentation of the glycan epitope could influence its recognition by the re-
ceptor protein. Two biantennary complex-type undecasaccharides-Asn (ligands 3 and 4, Figure S1),
bearing a2,3- and a2,6-linked sialic acid at glycan antennae termini, were used. Interestingly, NMR and
computational methods suggested that only the outermost portion of the complex glycoconjugates was
accommodated in the binding pocket of the protein with the inner residues not participating in the molec-
ular recognition (Figure 5). Analysis of STD NMR spectra acquired in the presence of Siglec-10 (Figure S7)
clearly revealed the key role of the sialic acid in the recognition and binding process, and the epitope map-
ping of glycans 3 and 4 was indeed comparable with those obtained with the smaller ligands 1 and 2; the
acetyl group of the sialic acid displayed the strongest STD intensity and other STD enhancementsiScience 23, 101231, June 26, 2020 9
Figure 5. Molecular Recognition of Longer N-glycans by Siglec-10
(A) Full view of the 3-D complexes of ligand 3 (green) and ligand 4 (pink) using Siglec-10 (model IV) structural template
obtained by docking calculations.
(B) Superimposition of ligand 1 (yellow) and ligand 3 (green) in the Siglec-10 (model IV) binding site.




Articlecorresponded to H-5/H-9 protons of the Neu5Ac moiety. Furthermore, STD effects for H-4 and H-6 of the
galactose unit, in the case of the a2,6 undecasaccharide, and for H-3/H-6, in the case of the a2,3-linked sia-
loglycan, were observed. In addition, the protons belonging to the other sugar residues of the branches
and the N-glycan pentasaccharide core did not appear in the STD spectra, clearly suggesting that the
recognition was mainly driven by the Neu5Ac-Gal moieties. The other sugar residues were indeed solvent
exposed and far from the protein surface.
These results were further confirmed by modeling 3 and 4 into the Siglec-10 binding site (Figure 5). As
shown in the resulting three-dimensional structures of the corresponding complexes, good predicted
binding poses were obtained for both ligands, confirming that longer complex-type glycans can be accom-
modated in the protein binding pocket, displaying a similar network of interactions with respect to those
established by sialoglycans 1 and 2 upon protein binding.
In detail, as expected, both complex glycoconjugates interacted with Siglec-10 binding-site residues
mostly via the Neu5Acmoiety. Indeed, the ionized carboxylic group of sialic acid formed a polar interaction
with the lateral chain of Arg-119 and Tyr-128 contributed significantly to the recognition establishing CHp




ArticleIn the case of sialoglycan 3, the hydroxyl groups of Neu5Ac lateral chain were also involved in hydrogen
bonds with Arg-127 and Arg-20. The Sia acetamidemoiety formed a hydrogen bond with the Arg-127 back-
bone, whereas the Phe-21 residue on Siglec-10 was responsible for the hydrophobic interaction with
Neu5Ac acetyl group. The Gal moiety was also placed inside the binding pocket, making polar contacts
with Glu-66 and Asn-129 residues. A hydrogen bond between Asn-129 and the hydroxyl group at C-9 of
Neu5Ac was instead observed for sialoglycan 4 in the interaction with Siglec-10. As in 3, the Gal moiety
of 4was in close proximity to the receptor surface, making polar contacts with Glu-66 residue. In agreement
with NMR results, in both 3D complexes, the inner residues of the oligosaccharides were far from the re-
ceptor surface and did not directly contribute to the binding. Of note, the conformation of the sialylated
lactosamine branches of 3 and 4, involved in the interaction with Siglec-10, was comparable with that adop-
ted by the sialoglycans 1 and 2, respectively, upon binding. Moreover, independently from the sialic acid
linkage to the adjacent galactose moiety, both complex glycans preferentially exhibited an extended
conformation when placed in the binding site of the protein, although a certain flexibility around the
Man-a-(1,6)-Man glycosidic linkage was observed (Figure 5).Conclusions
In summary, the interaction of Siglec-10 with differently sialylated glycans was here investigated by an in-
tegrated approach based on NMR, docking, and molecular modeling. Although the crystal structure of Si-
glec-10 has not been solved yet, the orthogonal methods applied here allowed a molecular description of
the recognition and binding processes driving Siglec-10-sialyloglycans complexes, providing unique infor-
mation about dynamics and molecular interactions. The ligands’ epitopes in their bound conformations
were indeed profiled and consistent 3D models of the interactions were presented.
A comparison of the epitope maps obtained for a2,3- and a2,6-sialoglycans, which constitute the terminal
end of the canonical sialylated complex-type N-glycans exposed on mammalian cells, highlighted that
in each case the binding process to Siglec-10 was mainly driven by the sialic acid moiety, giving a 100%
STDepitope fit, and galactose unit, whereas the N-acetylglucosamine pointed away from Siglec-10 binding
pocket. On the other hand, some differences were evident from the STD-derived epitope maps, indicating
that ligand 2 established less contacts within the protein binding pocket, as demonstrated by the lower
involvement in the interaction of protons H-5, H-8, and H-9 of sialic acid and of the adjacent galactose unit.
The bound conformations of a2,3- and a2,6-sialoglycans were obtained by combining NOE-derived data
with MM and MD simulations. The g- conformer of the a2,3-sialoglycans was selected upon binding to Si-
glec-10; instead, the a2,6-sialoglycans mainly assumed a bent gt conformation both in the free and bound
states. Thus, our data suggested that, upon binding, the terminal portion of sialylated glycan chains pref-
erentially adopted a cone-like or an umbrella-like topology depending on the sialic acid linkage to the un-
derlying galactose residue.
Extensive homology modeling studies provided a 3-D model of human Siglec-10. Then, further computa-
tional approaches, namely docking and MD studies, together with CORCEMA-ST protocol, were used to
either indirectly support the reliability of the 3-D model of Siglec-10 and to obtain structural insights into
the molecular basis of N-glycan recognition by Siglec-10. Our three-dimensional models of the Siglec-
10/sialoglycan complexes highlighted the architecture of the binding site essentially composed of hydro-
phobic (Phe-21), polar (Tyr-128, Asn-129), basic (Arg-119, Arg-127), and acid (Glu-66) residues. In detail, the
Arg-119, Arg-128, Asn-129 residues were directly involved in the interaction with sialic acid, suggesting they
shaped a region relevant for the molecular recognition, matching those previously reported for other stud-
iedmembers of the Siglec family (Crocker et al., 2007). Moreover, we observed that the CC’ loop belonging
to the Siglec-10 V-set domain established key interactions with the adjacent galactose moiety that appears
to participate in the interaction process, whereas the GlcNAc residue showed no relevant contribution to
the binding.
The ability of Siglec-10 to recognize both a-2,3 and a-2,6 linkages to a similar extent indicates a lower spec-
ificity (Macauley et al., 2014; Blixt et al., 2003) compared with other homologous Siglecs, likely due to a wider
binding site. The CC0 loop region predicted for Siglec-10, indeed, points outward to the binding residues, in
contrast to some other CD33-like Siglecs (for example, Siglec-5, Siglec-3, and Siglec-8) but as already re-
ported for Sialoadhesin, Siglec-4, and Siglec-7 (Figure 6). This could account for the greater capacity of the
protein to flexibly accommodate sialoglycans with different shapes and conformation, a2,3-sialoglycan 1 iniScience 23, 101231, June 26, 2020 11
Figure 6. Siglec-10 CC0 Loop Shape
Comparison of Siglec-10 (model IV) loop region with other CD33-like Siglec, namely, Siglec-5 (PDB ID: 2zg2) and Siglec-7




Articleits extended topology and the a2,6-sialoglycan 2 in a more compact bent conformation. Furthermore, also
longer biantennary glycoconjugates,ligands 3 and 4 (Figure S1), could be accommodated in the protein bind-
ing pocket where the terminal ends preferentially adopted a cone-like or an umbrella-like topology respec-
tively. Their outermost region was directly involved in polar and hydrophobic interactions with amino-acidic
residues, whereas the inner moieties of the oligosaccharides pointed away from the protein surface. Of note,
for both a2,3- and a2,6-linked complex type N-glycans 3 and 4, an extended conformation of the entire un-
decasaccharide seemed to be preferred (Figure 5) and, interestingly, the topology of the terminal sialylated
portions oriented differently the long saccharide chains with respect to the binding site.
Given the pivotal roles that Siglecs play in the regulation of immune cell functions, they have been widely
recognized as targets for the development of immunotherapeutics against a broad range of diseases. The
receptor-sialoglycan interactions can mediate events like cell adhesion, signaling and interaction, inhibition
or regulation of the immune cell activation, and uptake of sialylated pathogens. The disturbance of the sialic
acid-Siglec axis can contribute to the onset and development of diseases such as autoimmunity, infection,
inflammation, aging, and cancer. Worthy of note is the role played by the inhibitory receptor Siglec-10 in
several crucial patho-physiological processes. Siglec-10 is engaged by sialylated glycoproteins, as tumor-ex-
pressed CD24, to promote the tumor immune evasion, or by dangerous pathogens, including Campylo-
bacter, to subvert the host immune system. Although our understanding of the biological roles of Siglecs
has been expanding over the past decade, a detailed molecular knowledge of their interaction with glycan
ligands is still an unmet challenge. For instance, despite Siglec-10 is an appealing target for the development
of glyco-based immunotherapy (Angata et al., 2015), neither the three-dimensional structure of protein nor
the molecular basis of its interactions with complex glycans had been previously unraveled. Thus, the out-
comes shown here have improved our knowledge of the molecular mechanisms occurring between Siglec-
10 and sialylated glycans, providing a structural point of view for the design and development of high-affinity
ligands, in their bioactive conformations, able to control the receptor functionality.Limitation of the Study
This study describes the interactions of the biologically relevant protein Siglec-10 with naturally occurring
sialoglycans by using different biophysical techniques, including ELISA, steady-state fluorescence, and
mainly NMR spectroscopy, combined with computational chemistry and CORCEMA-ST calculations. In
the absence of high-resolution structural information on the receptor Siglec-10, we resorted to homology
modeling following a convergent approach of combining different templates for the homology calculation
and different modeling approaches to validate the generated models (docking, MD simulations, COR-
CEMA-ST). However, the structural conclusions we derived from homology modeling will require the defi-




ArticleFurther development of this work may also include the search of natural ligands for Siglec-10. The func-
tional significance of the Siglec-10/CD24 interaction has been previously shown; however, other heavily






This study did not generate new unique reagents.
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Figure S1 Related to Figures 1 and 5. Structures of sialylated ligands used in this study. The two 
trisaccharides, Neu5Ac--(2→3)-Gal--(1→4)-GlcNAc, ligand 1, and Neu5Ac--(2→6)-Gal--(1→4)-GlcNAc, 
ligand 2 differ in the type of glicosidic linkage at the non-reducing end; the longer glycans, ligands 3 and 4, are 
commonly exposed on mammalian cells. 
  






Figure S2 Related to Figures 2 and 3. Conformational analysis of ligands 1 and 2. Left panel: NOESY 
spectrum (a) of ligand 1 in its free state (mixing time of 600ms) and tr-NOESY spectrum (b) of ligand 1 bound 
to Siglec-10 (mixing time of 400ms) at 283K. The protein-ligand molar ratio was set at 1:10. Some differences 
in terms of signal intensities were observed comparing the free and bound state. Right panel: ROESY 
spectrum (a) of ligand 2 in its free state (mixing time of 450ms) and tr-NOESY spectrum (b) of ligand 2 bound 



















































Table S1 Related to Figure 2. Experimental STD epitopes of trisaccharide 1 bound to Siglec-10. 
STD intensities of ligand 1 bound to Siglec-10 experimentally calculated at different saturation times, using 
the monoexponential equation STD(tsat) = STDmax× [1-exp(-ksat× tsat)]. 
 
1
H  STDmax  Ksat  STD (fit)  
STD epitopes 
(fit)  
Ac Neu5Ac  1.8331  0.1871  0.342973  100%  
H6 Neu5Ac  0.5615 0.5144 0.288836  84.2%  
H7 Neu5Ac  0.5251  0.5249  0.275624  80.4%  
H8 Neu5Ac  0.263  0.7105  0.186862  54.4%  
H9S Neu5Ac  0.3128  0.5849  0.182957  53.3%  
H4 Gal  0.2017  0.5974  0.120496  35.1%  
H3 Gal  0.2919  0.3848  0.112323  32.7%  
H5 Neu5Ac  0.2243  0.6552  0.146961  42.8%  
H3eq Neu5Ac  0.1651  0.7792  0.128646  37.5%  
 
 
Table S2 Related to Figure 3. Experimental STD epitopes of trisaccharide 2 bound to Siglec-10. 
STD intensities of ligand 2 bound to Siglec-10 experimentally calculated at different saturation times, using 
the monoexponential equation STD(tsat) = STDmax× [1-exp(-ksat× tsat)]. 
 
1
H  STDmax  Ksat  STD (fit)  STD epitopes (fit)  
KAc Neu5Ac  9.0345  0.2863  2.586577  100%  
H6 Neu5Ac  4.4377  0.4472  1.984539  76.7%  
H7 Neu5Ac  3.7108  0.4639  1.72144  66.6%  
H3eq Neu5Ac  0.8736  0.5546  0.484499  18.7%  
H3ax Neu5Ac  1.1098  0.7396  0.820808  31.7%  
H9S Neu5Ac  1.4138  0.5461  0.772076  29.8%  
H5 Neu5Ac  1.684  0.3123  0.525913  20.3%  
H6R Gal  0.5481  0.7821  0.428669  16.6%  





a) Figure S3 Related to Figure 4. a) Sequence alignment of Siglec-10 CRD (aa 17-144) respect to the 
CD33-like Siglecs templates, namely Siglec-3, Siglec-5, Siglec-7 , Siglec-8. The residues responsible for the 
binding of sialylated glycans are highlighted in green. b) Superimposition of the best Siglec-10 homology-
based model (orange) and the X-ray crystal structures from other Siglec members. The residues of Siglec-10 
that interacted with the sialic acid moiety which are reported to be crucial for the interaction with sialylated 
glycans are shown as sticks. The Arg in position 119 in Siglec-10 was indeed conserved in all the Siglecs, 




















Figure S4 Related to Figure 4. A. Structural features of Siglec-10 selected model. a) Superimposition of 
the selected homology models. Relevant differences can be observed only in one of the variable Siglec region 
that is the CC’ loop. b) Structure of the best Siglec-10 model obtained by means of Swiss Model by using 
Siglec-7 as template. The secondary structure elements are indicated according to Siglecs V-set domain 
nomenclature. B Analysis from the MD simulations of the best homology models. a) Root mean square 
deviation (RMSD) of the backbone of Model I (orange), Model II (purple), Model III (green), Model IV (cyan) b) 
Root mean square fluctuation (RMSF) of the backbone of the different models of Siglec-10 c-d) RMSD of the 
backbone of the important loop regions (CC’-loop) on the left and  (GG’ -loop) on the right. C MD simulation 
trajectory analysis of different Siglec-10/ligand complexes from homology modeling and docking 
studies. a) MD simulation analysis of model III/1 complex (-g conformer). b) MD simulation analysis of model 
III/2 complex (gt conformer) c) MD simulation analysis of model IV/2 (gg conformer) complex.  d) MD simulation 
analysis of model IV/2 (tg conformer) complex. The ligand in complexes a) and c) showed low stability during 
















Figure S5 Related to Figure 4. MD simulation trajectory analysis of ligands/model IV complex (upper panel) 
and trisaccharide 2/model IV complex (lower panel). Upper panel A: a) Dihedrals , ψ of Neu5Ac-α-(2,3)-Gal 
linkage fluctuation in MD simulation of the bound state (model IV); b) RMSD plot of trisaccharide 1 (-g 
conformer) in complex with Siglec-10 CRD (model IV). c) Representative intermolecular distances between 
Neu5Ac unit and the Siglec-10 residues calculated along the simulation. According to this figure several 
hydrogen bonds in the complex can be expected. Lower panel B: a) Dihedrals , ψ,  of Neu5Ac-α-(2,6)-Gal 
linkage fluctuation in MD simulation of the bound state; b) RMSD plot of trisaccharide 2 (gt conformer) in 
complex with Siglec-10 CRD (model IV). c) Representative intermolecular distances between Neu5Ac unit and 
the Siglec-10 residues calculated along the simulation. According to this figure several hydrogen bonds in the 













Figure S6 Related to Figure 4: CORCEMA-ST analysis of different models of binding generated by the 
modelling studies with 1 (upper panel) and 2 (lower panel).  
For all the reported models, the profile of the experimental STD data was not similar from that of the theoretical 
STD effects. The predicted STD values were very different from the experimental ones for several protons 










































































Col 1 vs Col 2 


























Col 1 vs Col 2 































Figure S7 Related to Figure 5. Analysis of the interactions between longer N-glycans and Siglec-
10. a) STD NMR interaction between Siglec-10 and undecasaccharide 3. b) Binding pose predicted by the 
docking of the undecasaccharide 3 bound form into the binding pocket of Siglec-10 model. c) STD NMR 
analysis of the interaction between Siglec-10 and undecasaccharide 4; d) Binding pose predicted by the 


















NMR analysis: All NMR experiments were recorded on a Bruker 600-MHz DRX equipped with a cryo probe 
and all the samples were dissolved in 50mM phosphate buffer, pH 7.4. Data acquisition and processing were 
performed with TOPSPIN 3.2 software.  
Data sets of 4096x512 (t1 x t2) points and zero-filled in the F1 dimension up to 4096x2048 points were 
used when homonuclear spectra were measured. Before Fourier transformation, a cosine-bell function was 
used. Heteronuclear single quantum coherence (HSQC) experiments were recorded in the 1H-detected mode 
by single quantum coherence with proton decoupling in the 13C domain, with data sets of 2048x256 points. 
The phase-sensitive mode by the method of States et al. was used in all the experiments (States et al., 1982).  
Tr-NOESY analysis: For ligand 1, one-dimensional selective NOE experiments were acquired at mixing 
times ranging from 50-800ms, at 283K, following the selective excitation of proton H3 of Gal residue. 
For ligand 2, homonuclear 2D 1H-1H NOESY experiments were performed by using data sets of 4096x512 
points and mixing times between 50 and 800 ms.  
The protein: ligand ratio varied from 1:10 to 1:50. Proton – proton cross relaxation rates were measured 
integrating the NOE signals of interest. The raw data were normalized against the corresponding 
diagonal/selectively irradiated peak that was fitted to an exponential decay function and extrapolated back to 
an intensity of 100% at zero mixing time. Once normalized, the intensities were plotted against the mixing 
times and the build-up curves were fitted to an exponential equation of the form f(x)= A*(1-expt(-b*x))*(expt(-
c*t)), with A, b and c being adjustable parameters. The initial slope at 0 mixing time (σ) of each curve was used 
to calculate the experimental distances (rij) by employing the isolated spin pair approximation. The intra-
residue NOE contacts used as reference for distance determinations were: H1-H3 of galactose moiety for 
ligand 1 and H1-H5 of the N-acetylglucosamine residue A was for ligand 2. The experimental error in the 
calculated proton-proton distances is estimated to be less than ± 10%. 
STD NMR analysis: Control experiments with the ligands in the absence of the protein were performed to 
optimize STD NMR parameters. 
STD NMR experiments were recorded with 32 k data points and zero-filled up to 64 k data points prior to 
processing. The protein/ligand molar ratio spanned from 1:50 to 1:200. 40 Gauss pulses with a length of 50 
ms were used to selectively irradiate the protein resonances by using the on-resonance pulse at 7.5 ppm, 
while the off-resonance pulse frequency was at 40 ppm. The unwanted broad signals of the receptor were 
reduced by applying a 20 ms spin lock pulse.  
The fractional STD effects were calculated by use of (I0 – Isat)/I0, where Isat is the intensity of the signal in 
the STD NMR spectrum and I0 is the peak intensity of an unsaturated reference spectrum (off-resonance). 
The construction of STD build up curves was performed by fitting the saturation time data to a monoexponential 
equation of the form: STD = STDmax[1 – exp(–ksatt)], where STD is for the STD signal intensity of a given proton 
at a saturation time t, STDmax stands for the asymptotic maximum of the curve, and ksat represents the observed 
saturation rate constant measuring the speed of STD build-up. The value of STDfit was derived by the slope of 
the STD build-up curve at a saturation time of 0. Once calculated both STDfit and Ksat values, all the intensities 
of different protons ligand were normalized to the largest STDfit, giving STDepitopes fit.  
CORCEMA-ST protocol: CORCEMA-ST protocol has been used as previously described (Wen et al., 2005; 
Bhunia et al., 2004). The pdb coordinates of complexes were generated from Docking and MD analyses and 
the conformation of the ligand was considered to be the same in both free and bound state. The input variables, 
including the concentration of the ligand and the protein, were deduced experimentally. The dissociation 
constants (KD) were set in the range of 10−3–10−6 M and modified further to get the best fit. A binding site cut-
off of 8 Å was employed. After the computation of R matrix and the calculation of spectral densities, the 
predicted fractional intensity changes for each ligand protons were compared to the experimental STD effects 
by using a NOE R factor, a normalized root-means square deviation (RMSD) value. 
Preparation of glycans: Ligand 1 and 2 were purchased from Tokyo Chemical Industry Co., Ltd. (Product 
Number: N0949, N0950). Ligand 3 and 4 were provided from GlyTech, Inc (Kajihara et al., 2004). 
Protein expression and purification: A cDNA encoding a recombinant form of human Siglec-10 containing  
Chinese Hamster Ovary cell line stably expressing the 5 3 N-terminal Ig-like domains of human Siglec-10 
CD22 fused to the Fc region of humanmouse IgG1G2b was prepared as described previously (Munday et al., 
2001), cloned into the pEE14 glutamine synthetase expression system (Bebbington et al., 1992) and 
transfected into kindly provided by Dr Ajit Varki (University of California San Diego) Chinese Hamster Ovary 
(CHO) cells. A CHO cell clone stably expressing Siglec-10-Fc was expanded in glutamine-free Glasgow’s 
modification of Eagles Medium (GMEM) containing 200 micromolar L-methionine sulfoximine and 10% FCS. 
Once cells were ~90% confluent, the medium was switched to GMEM + 0.5% Hyclone Fetalclone II (low IgG) 
and cells left for up to 7 days. Three Cells were expanded in flasks in Hams F10 + 10% FCS and when 
confluent the medium was changed to Hams F10 + 0.5% FCS and cells incubated for up to 7 days. 4 litres of 
supernatants were pooled, 0.2 µM filtered and passed over a 1.0 ml protein A-Sepharose column. Following 
washing with 100 ml PBS, the Siglec-10-Fc protein was eluted with 0.1 M glycine pH 3.0 and neutralised with 
one tenth volume of 1.0 M Tris buffer pH 8.0. Fractions containing > 0.1 mg/ml protein were pooled, dialysed 
against PBS and stored at -80C. Purity of the protein was assessed by SDS-PAGE under reducing and non-
reducing conditions followed by Coomassie Blue staining. 
Homology modeling. The carbohydrate recognition domain of human Siglec-10 was considered for 
computational 3D structure calculation by homology modeling. The sequence encoding for the human Siglec-
10 (acces.No. Q96LC7.3) was extracted from NCBI (http://www.ncbi.nlm.nih.gov). The carbohydrate 
recognition domain was identified by submitting the query sequence to CD-search (Marchler-Bauer et al., 
2004; Marchler-Bauer et al., 2017). As result, the region between the residues 23-140 of the protein query was 
found to match (‘specific hit’) to the Immunoglobulin (Ig) domain at the N terminus of Siglec (acces.No. 
cd05712). The previous interval was then submitted to the BLAST search (Altschul et al., 1990; Gish et al., 
1993) , using protein data bank as database to identify potential templates for the homology modeling of Siglec-
10. Siglec-8 (PDB–ID:2N7A), Siglec-7 (PDB-ID:2HRL), Siglec-5 (PDB-ID:2ZG2) and Siglec-3 (PDB-ID:5IHB) 
were selected as the templates because of the highest identity (47-56%) and query cover (85-99%). For each 
template, four homology  models were generated using four different servers: SWISS-MODEL (Arnold et al., 
2006; Biasini et al., 2014) , I-TASSER (Roy et al., 2010; Yang et al., 2015) , PHYRE2 (Kelley et al., 2015), and 
RAPTOR-X (Kallberg et al., 2012).(Figures S3-S4A). To select the best models, detailed analysis was 
performed, focusing on the orientation of the binding site residues and the flaking loops. The models derived 
from I-TASSER, and PHYRE-2 were discarded because the structures did not have coherence with the 
experimental 3D structures of the homologous proteins. Thus, computational studies were performed using 
the 3D structures obtained from SWISS-MODEL and RAPTOR-X, which were submitted to molecular 
dynamics (MD) simulations of 100 ns to optimize the geometry. To assess the quality of the homology models, 
the results were compared to the MD simulation (100 ns) performed with the crystal structure of Siglec-3 (PDB-
ID: 5IHB), which was carried out using the same parameters. The macromolecule was chosen as reference 
because of the similarity to Siglec-10, in terms of binding specificity and affinity toward sialylated glycans (Varki 
et al., 2006).  
Each of the computed models displayed high similarity in terms of 2D and 3D structure among them and also 
in comparison to the corresponding templates, showing a nearly invariant canonical V-set Ig-domain fold. As 
can be expected by the sequence alignment (Figure S3A), the superimposition to other Siglec crystal 
structures revealed some diversity concerning the amino acids constituting the binding site (Figure S3B), 
pointing to a putative role in the specificity of recognition of sialylated glycans. Nevertheless, the selected 
models exhibited different shape in the CC’ loop, probably due to the lower sequence similarity in that region 
with respect to the structural templates (Figure S3), leading to difficulties in the loop conformation prediction. 
For this reason, the mobility of the CC’ and GG’-loop of the selected models has been investigated during the 
dynamics (Figures S4A and B). From the MD simulation results was observed that the models obtained using 
Siglec-3 and Siglec-7 as templates (both the Swiss-Model and the Raptor-X models) displayed higher stability 
along the simulations and therefore they were used for the docking calculations (Figure S4). 
Molecular dynamics simulations. By means of MD simulations as implemented in AMBER 14 suite of 
programs it was possible to investigate the ligands behavior in solution, to assess the stability of the homology 
models, the mobility of the loops and the stability of the docking poses. Missing hydrogen atoms were added, 
and protonation state of ionisable groups was computed by using Maestro Protein Preparation Wizard 
(Schrodinger et al., 2012; Schrodinger et al., 2012; Schrodinger et al., 2012)  Atom types and charges were 
assigned according to AMBER ff14SB, for the homology models and GLYCAM-06j-1 force field for the ligands. 
To simulate the aqueous environment the homology models and ligands were hydrated by using octahedral 
boxes containing explicit TIP3P water molecules extending 10 Å away from any atom. Counter ions were 
added to neutralize the system by using the Leap module. Minimization was performed using Sander and MD 
simulations were carried out using the CUDA, which are distributed within the AMBER 14 package. The smooth 
particle mesh Ewald method was used to represent the electrostatic attractions in the system while each 
simulation was under periodic boundary conditions, and the grid spacing was 1 Å. Initial annealing of the 
system occurred steadily and lightly from 100 °K to 300 °K over 25 ps. Temperature was kept constant at 300 
°K during 50 ps with progressive energy minimizations and a solute restraint. The restraints were gradually 
released by the solute, which was closely followed by a 20 ps heating period which went from 100° K to 300° 
K, once completed the restraints were removedThe systems then advanced in an isothermal-isobaric 
ensemble. Long-range electrostatic interactions were accounted for by means of the particle mesh Ewald 
approach applying periodic boundary conditions. Each of the simulations lasted 100 ns. Coordinates were 
archived in order to acquire 1000 structures of the progression of the dynamics. Trajectories were analysed 
with the ptraj module included in the AMBER14 software package and visualized with VMD molecular 
visualization program (Roe et al., 2013). 
Ligand-protein docking calculations.  
Preparation of the macromolecules. 3D coordinates of Siglec-10 homology models were used for docking 
purposes. In addition, the docking calculations were performed by using the 1 ns average structure extracted 
by MD simulations of the computed Siglec 10 models. Then, each structure was submitted to 100 000 steps 
of steepest descent minimization with MacroModel and optimized with AMBER force field, before being used 
for docking calculations. Quality of the minimized models was verified using the procheck online resource 
(Laskowski et al., 1993) that displayed Ramachandran plot of the structures. 
Building of ligands. The 3D coordinates of [Neu5Ac-α-(2,3)-Gal-β-(1,4)-GlcNAc-β] and [Neu5Ac-α-(2,6)-
Gal-β-(1,4)-GlcNAc-β] were built with the help of xLEAP using the GLYCAM_06j-1 force field parameters. It is 
worth to note that the relative orientation of saccharide units is expressed in terms of the glycosidic linkage 
torsion angles ϕ and ψ, for α (2-3) linkage and ϕ and ψ and ω for α (2-6) linkage. Therefore to investigate the 
conformational behavior of the ligands, the three conformers (g-,g+, t) of Neu5Ac-α-(2,3)-Gal-β-(1,4) glycosidic 
linkage and the three rotamers (gt, gg, tg) of Neu5Ac-α-(2,6)-Gal-β were considered for docking calculations. 
For each conformer, the bonds were parametrised and the geometries were optimized by 100000 step of 
steepest descent minimization with OPLS3 force field by using Macro Model. The resulting structures were 
submitted to 100 ns MD simulations to assess the stability. Ligands were prepared for docking calculations 
using AutoDockTools, setting all rotatable bonds free to move, except for the glycosidic linkages, during the 
docking calculations. 
Docking calculations. Docking calculations of all compounds were performed by using AutoDock 4.2.2. 
(Morris et al., 2009). Analysis of the docking poses was performed with AutoDockTools. The docking protocol 
was validated by carrying out the docking of Siglec-3 crystallographic structure in complex with α(2-3) Neu5Ac-
Gal ligand (PDB-ID: 5J06). The 3D structure of α(2-3) Sia-Gal was extracted from the crystallographic structure 
of Siglec-3.The grid point spacing was set at 0.375 Ǻ, and a hexahedral box was built with x, y, z dimensions: 
64 Ǻ, 46 Ǻ, 56 Ǻ centered in the centroid position among residues Arg119, Arg127 and Asn129 for Siglec-10 
models; Arg121, Lys128 and Ser130 for Siglec-3. A total of 200 runs using Lamarckian Genetic algorithm was 
performed, with a population size of 100, and 250000 energy evaluations.  
Molecular modelling and CORCEMA of 1 and 2 in complex with Siglec-10  
 Docking calculations of trisaccharide 1 in its three possible conformations within the selected modeled 
structures (model I, model II, model III, model IV) were performed.  
The docking results showed that no reasonable binding pose was predicted for the models I and II in none of 
the possible ligand conformations. Additionally, the docking calculations performed using 1 ns average 
structure calculated by MD simulations didn’t led to rational representation of the interacting surface. The 
models III and IV, instead, resulted in binding poses consistent to the experimental STD and NOE data. Also, 
in these complexes, the polar contacts established between the ligand and the receptor were in agreement 
with those observed for experimental binding poses of homologous proteins with similar ligands (Zhuravleva 
et al., 2008; Attrill et al., 2006).The selected protein-ligand complexes were submitted to 100 ns MD 
simulations. In detail, by comparing the 3D complexes obtained from the docking of trisaccharide 1 in the g– 
conformation with the two foremost structural models, it was noted that the higher stability along the simulation 
was achieved by using model IV rather than model III (Figures S4C and S5Al). As a consequence, the receptor 
model III was excluded from the CORCEMA ST characterization.  
Then, the 3D complexes obtained from model IV homology, which presented different trisaccharide 1 geometry 
(g and t conformers), were submitted to CORCEMA-ST calculation giving a R NOE value significantly higher 
than model IV/1 complex (Figure S6A). This outcome permitted to further assess the selection of the g– 
conformer upon binding. 
Docking calculations of ligand 2 were performed in the selected Siglec-10 modeled structures. From the 
docking studies three reliable binding poses of 2 were predicted using model IV as receptor. The binding poses 
differed essentially for the value of the  angle around the Neu5Ac (2,6) Gal glycosidic linkage: In the three 
selected binding poses, one pose of the ligand in the gt conformation (ω= 60º), one pose in the tg conformation 
(ω= 180º) and the last in the gg conformation (ω= -60º), the ligand was placed with good orientation into the 
binding site of Siglec-10. Therefore, the obtained complexes were submitted to 100 ns MD simulations to 
assess the stability (Figures S4C and S5B). From the simulation results it was possible to observe significantly 
higher stability for the gt conformer complex. Indeed, the trisaccharide 2 binding mode within the Siglec-10 
model IV structure showed stability until 70 ns and maintained all the described polar interactions without 
restrictions. It is worth to note that the CORCEMA- ST allowed to finally select the best complex, as for the 
model IV/ 2 tg and gg conformers, the predicted STD values were very different from the experimental ones 
for many protons (Figure S6B).  
Steady-state fluorescence spectroscopy 
Steady-state fluorescence spectra have been acquired on a Fluoromax-4 spectrofluorometer (Horiba, Edison, 
NJ, USA) at the fixed temperature of 5°C. Emission spectra were recorded in the emission range of 290–500 
nm upon excitation at 280 nm. The slit widths were fixed at 4 nm for the excitation and 10 nm for the emission 
wavelength. A quartz cuvette with a path length of 1 cm and a chamber volume of 1 mL was used under 
constant stirring. A 0.9 mL volume of protein solution at fixed concentration of 0.2 μM was titrated by adding 
small aliquots (1–20 μL of a ligand stock solution of 500 μM) of trisaccharide 1 and 2. The PBS buffer at pH 
7.4 was used for all solutions. The optical density of the solution at the excitation wavelength was kept less 
than 0.05. Small errors due to dilution upon ligand additions were neglected. The protein fluorescence was 
found to quench in the presence of the ligands. The binding curve was obtained by plotting F/F0 values versus 

















where F0 and F are the integrated areas of the emission spectra in the absence and the presence of ligands, 
and FY  and F  are the quantum yield of the fluorophores in the complex and in the protein, respectively. The 









where [ ]t ba F K= , 1 [ ]t bb Y K= + and [ ]t bc Y K= ; [ ]tF  and [ ]tY represent the total concentration of protein 
and ligand, respectively. 
 
ELISA: a solution of 50 µL of synthetic polyacrylamide (PAA) polymers functionalized with Neu5Acα2-3Galβ1-
4Glcβ-NHCOCH2NH2 or Neu5Acα2-6Galβ1-4Glcβ-OCH2CH2NH2 (purchased from GlycoNZ, Auckland, New 
Zealand, carrying the same moles of carbohydrate) at 200 µg/mL, or a solution of 50 µL of synthetic glyco-
peptides containing sialylated N-glycans at 1mg/mL, in PBS (10mM, pH=7.4), were used to coat the Nunc 
MaxiSorp plate 2h at room temperature. After discarding and washing with PBS (1x150µL), the wells were 
blocked with 100 µL of 1% BSA (Sigma-Aldrich, lyophilized powder, ≥96%, agarose gel electrophoresis) in 
PBS at room temperature for 30 min. The blocking solution was discarded and 50µL of Fc-Siglec-10 at 1 µg/mL 
(Recombinant Human Siglec-10 Fc Chimera Protein from R&D) in assay buffer (0.5% BSA) were added to the 
wells. After 1h at 37°C , the wells were washed with PBS (2x150µL) and then 100 µL of anti-human horseradish 
peroxidase (0.8 µg/mL, life technologies, Novex® Goat anti-Human IgG-HRP) were added. After 30 min at 
room temperature, the wells were washed with PBS (2x150µL). Finally, 100 µL of substrate solution (3,3′,5,5′-
Tetramethylbenzidine, TMB, in citric/acetate buffer, pH=4, and H2O2) were added and after 5 min incubation 
at room temperature the reaction was stopped with 50 µL of H2SO4 (0.8 M) and the optical density (OD) was 
measured at 450 nm in an ELISA reader. The experiment was performed in duplicate and data were 
normalized over the signal at 450 nm from the BSA-containing wells. 
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